SCA
AERI

Secor Capital Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Secor Capital Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,553
Closed -$272K – 673
2017
Q4 		$272K Buy
+4,553
New +$276K 0.01% 425
2017
Q2 		– Sell
-19,875
Closed -$901K – 604
2017
Q1 		$901K Buy
+19,875
New +$886K 0.1% 254
2015
Q2 		– Sell
-6,560
Closed -$206K – 579
2015
Q1 		$206K Buy
+6,560
New +$190K 0.08% 394

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Secor Capital Advisors's AERI Position: Q1 2018 in Review

Secor Capital Advisors sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 4,553 shares — an estimated $272K sold.

Secor Capital Advisors first reported a position in AERI in Q1 2015 and held it in 3 quarters. The position peaked at $901K in Q1 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • Secor Capital Advisors reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 4,553 Aerie Pharmaceuticals shares in Q1 2018, an estimated $272K.
  • Secor Capital Advisors first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Secor Capital Advisors's Aerie Pharmaceuticals position peaked at $901K in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Secor Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.